Although the activation of VPAC1R/VPAC2R could have a beneficial effect, the correlation between the onset of motor discoordination and a specific decrease in PAC1R (Figure 12) strongly suggest that activation of PAC1R is a key therapeutic target for the treatment of HD. The gene discussed is VIPR2; the disease is Huntington disease.